Recently, HiMed Medical Technology (Suzhou) Co., Ltd. revealed that it has successfully closed a Series A+ funding round exceeding a hundred million yuan. This round was spearheaded by Puhua Capital, with contributions from Suzhou Guofa Venture Capital and Hangzhou Tiantang Silicon Valley, as well as ongoing backing from current shareholders. Yinglai Capital acted as the financial advisor. The raised capital will be allocated towards the registration and clinical trials of key products, the launch of clinical studies in Europe, and the development of new product pipelines. As the inaugural company in China—and only the second globally—capable of mass-producing small-diameter tissue-engineered blood vessels, HiMed Medical has secured five rounds of funding within just three years of operation. Its flagship product, the LineMatrix Naimaitong® biological vascular graft, has entered the National Medical Products Administration's (NMPA) expedited review pathway for innovative medical devices. The First-in-Man (FIM) clinical trial for this product has shown outstanding results in terms of patency rates and other performance indicators. The company was founded by Professor Qiu Xuefeng, who brings together a unique blend of clinical expertise, research acumen, and entrepreneurial spirit. By 2025, HiMed Medical has achieved several significant milestones, with investors voicing their strong anticipation and unwavering support for the company's future.